93 related articles for article (PubMed ID: 6362830)
1. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Costanzi JJ; Fletcher WS; Balcerzak SP; Taylor S; Eyre HJ; O'Bryan RM; Al-Sarraf M; Frank J
Cancer; 1984 Feb; 53(4):833-6. PubMed ID: 6362830
[TBL] [Abstract][Full Text] [Related]
2. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
3. Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Long HJ; Green SJ
Med Pediatr Oncol; 1986; 14(2):86-7. PubMed ID: 3713642
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Costanzi JJ; Al-Sarraf M; Groppe C; Bottomley R; Fabian C; Neidhart J; Dixon D
Med Pediatr Oncol; 1982; 10(3):251-8. PubMed ID: 7045615
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
[TBL] [Abstract][Full Text] [Related]
6. Actinomycin-D, levamisole chemoimmunotherapy of refractory malignant melanoma.
Hall SW; Benjamin RS; Lewinski U; Mavligit G
Cancer; 1979 Apr; 43(4):1195-200. PubMed ID: 445322
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
8. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Hill GJ; Krementz ET; Hill HZ
Cancer; 1984 Mar; 53(6):1299-305. PubMed ID: 6362841
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Perevodchikova NJ; Moros LW; Kogonia LM
Arch Geschwulstforsch; 1986; 56(4):273-81. PubMed ID: 3530176
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in high-risk malignant melanoma.
Karakousis CP; Emrich LJ
J Surg Oncol; 1987 Sep; 36(1):64-7. PubMed ID: 3306159
[TBL] [Abstract][Full Text] [Related]
13. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Robidoux A; Gutterman JU; Bodey GP; Hersh EM
Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
[TBL] [Abstract][Full Text] [Related]
14. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Creagan ET; Suman VJ; Dalton RJ; Pitot HC; Long HJ; Veeder MH; Vukov AM; Rowland KM; Krook JE; Michalak JC
J Clin Oncol; 1999 Jun; 17(6):1884-90. PubMed ID: 10561229
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Balch C; Troner M
Cancer; 1982 Apr; 49(7):1355-7. PubMed ID: 7037162
[TBL] [Abstract][Full Text] [Related]
17. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
Samson MK; Haas CD; Baker LH; Cummings G
Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
[TBL] [Abstract][Full Text] [Related]
18. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Tranum BL; Dixon D; Quagliana J; Neidhart J; Balcerzak SP; Costanzi JH; Fabian CJ; Neilan B; Maloney T; O'Bryan RM
Cancer Treat Rep; 1987 Jun; 71(6):643-4. PubMed ID: 3581104
[TBL] [Abstract][Full Text] [Related]
19. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
